RWP
LXRX icon

RWA Wealth Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

RWA Wealth Partners’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-13,289
Closed -$52K – 264
2021
Q4 		$52K Buy
+13,289
New +$64.5K ﹤0.01% 245

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RWA Wealth Partners's LXRX Position: Q1 2022 in Review

RWA Wealth Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2022, closing a stake of 13,289 shares — an estimated $52K sold.

RWA Wealth Partners first reported a position in LXRX in Q4 2021 and held it in 1 quarter. The position peaked at $52K in Q4 2021. 101 funds tracked by Wall St. Rank hold LXRX as of Q1 2022.

  • RWA Wealth Partners reported no remaining Lexicon Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • RWA Wealth Partners sold 13,289 Lexicon Pharmaceuticals shares in Q1 2022, an estimated $52K.
  • RWA Wealth Partners first reported a position in Lexicon Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • RWA Wealth Partners's Lexicon Pharmaceuticals position peaked at $52K in Q4 2021.
  • 101 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2022.

Based on RWA Wealth Partners's 13F filing for Q1 2022, filed 4 May 2022.